Antibody phage display technologies with special reference to angiogenesis

Area of Science:

• Biomedical Engineering
• Molecular Biology
• Oncology

Background:

• Blood vessel formation (angiogenesis) is vital for development, growth, and repair, but its dysregulation contributes to diseases like cancer and ischemic conditions.
• Current angiogenic therapies aim to stimulate or inhibit blood vessel growth, facing limitations in targeting specificity and reagent availability.
• Mouse monoclonal antibodies (Mabs) against angiogenic endothelial cells (ECs) can elicit autoantibody responses, precluding their therapeutic use.

Purpose of the Study:

• To review novel endothelial cell (EC) markers for improved angiogenic strategies.
• To discuss antibody targeting strategies for ECs in therapeutic applications.
• To highlight the limitations of current reagents and the need for new approaches.

Main Methods:

• Exploration of phage display technology for selecting antibodies, proteins, and peptides against EC antigens.
• Review of technologies for specific targeting of endothelial epitopes with high-affinity/avidity antibodies.
• Focus on unique or upregulated markers on angiogenic ECs.

Main Results:

• Identification of key markers such as vascular endothelial growth factor receptor (VEGFR) KDR, endoglin (CD105), and the ED-B domain of fibronectin (FN) on angiogenic ECs.
• Demonstration of advanced antibody targeting strategies for ECs.
• Highlighting the potential of phage display in generating novel reagents.

Conclusions:

• Novel EC markers and advanced antibody targeting strategies are essential for developing effective angiogenic therapies.
• Phage display technology offers a promising alternative to mouse Mabs for generating therapeutic reagents.
• Targeting specific EC markers holds significant potential for treating vascular diseases and inhibiting tumor growth.